Metformin is considered cardioprotective, since treatment with this agent is associated with a lower risk of mortality (compared with sulfonylurea or insulin therapy) in patients with diabetes and heart failure or MI, and with a decreased risk of non-fatal MI or stroke in patients with diabetes and MI [39]. Here, INS is linked to Stroke.